International definition of iMCD-TAFRO: future perspectives-Reference-Cited by-同舟云学术

International definition of iMCD-TAFRO: future perspectives

Published:2022 Issue:2 Volume:62 Page:73-78
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Nishimura Yoshito¹,Nishimura Midori Filiz²,Sato Yasuharu³

Affiliation:

1. Department of Medicine, John A. Burns School of Medicine, University of Hawai’i, Honolulu, HI, USA,

2. Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan,

3. Division of Pathophysiology, Okayama University Graduate School of Health Sciences, Okayama, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/62/2/62_21037/_pdf

Reference59 articles.

1. 1 Takai K, Nikkuni K, Shibuya H, Hashidate H. [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]. Rinsho Ketsueki. 2010; 51: 320-325.

2. 2 Kawabata H, Takai K, Kojima M et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013; 53: 57-61.

3. 3 Masaki Y, Kawabata H, Takai K et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016; 103: 686-692.

4. 4 Masaki Y, Kawabata H, Takai K et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020; 111: 155-158.

5. 5 Inoue M, Ankou M, Hua J et al. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. J Clin Exp Hematop. 2013; 53: 95-99.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO;Biomedicines;2024-06-14

2. TAFRO Syndrome and COVID-19;Biomedicines;2024-06-11

3. TAFRO Syndrome: Guidance for Managing Patients Presenting Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly;Biomedicines;2024-06-08

4. Immunology and targeted therapy in Castleman disease;Expert Review of Clinical Immunology;2024-05-27

5. TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?;Biomedicines;2024-03-14